Mariner
TBPH icon

Mariner’s Theravance Biopharma TBPH Stock Holding History

Mariner’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,697
Closed -$92.3K – 3171
2023
Q3 		$92.3K Sell
10,697
-3,095
-22% -$29.9K ﹤0.01% 2688
2023
Q2 		$143K Buy
13,792
+3,453
+33% +$38.1K ﹤0.01% 2565
2023
Q1 		$112K Buy
+10,339
New +$109K ﹤0.01% 2556

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Mariner's TBPH Position: Q4 2023 in Review

Mariner sold out of Theravance Biopharma (TBPH) in Q4 2023, closing a stake of 10,697 shares — an estimated $92.3K sold.

Mariner first reported a position in TBPH in Q1 2023 and held it in 3 quarters. The position peaked at $143K in Q2 2023. 118 funds tracked by Wall St. Rank hold TBPH as of Q4 2023.

  • Mariner reported no remaining Theravance Biopharma position as of Q4 2023 after selling out during the quarter.
  • Mariner sold 10,697 Theravance Biopharma shares in Q4 2023, an estimated $92.3K.
  • Mariner first reported a position in Theravance Biopharma in Q1 2023 and held it in 3 quarters.
  • Mariner's Theravance Biopharma position peaked at $143K in Q2 2023.
  • 118 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2023.

Based on Mariner's 13F filing for Q4 2023, filed 14 Feb 2024.